| Literature DB >> 30776675 |
Zuzana Kahounová1, Eva Slabáková2, Lucia Binó2, Ján Remšík1, Radek Fedr1, Jan Bouchal3, Radek Vrtěl4, Lucie Jurečková5, Volodymyr Porokh5, Darja Páralová6, Aleš Hampl7, Karel Souček8.
Abstract
Human induced pluripotent stem cell line was generated from commercially available primary human prostate fibroblasts HPrF derived from a fetus, aged 18-24 weeks of gestation. The fibroblast cell line was reprogrammed with Yamanaka factors (OCT4, SOX2, c-MYC, KLF4) using CytoTune™-iPS 2.0 Sendai Reprogramming Kit. Pluripotency of the derived transgene-free iPS cell line was confirmed both in vitro by detecting the expression of factors of pluripotency on a single-cell level, and in vivo using teratoma formation assay. This iPS cell line will be a useful tool for studying both normal prostate development and prostate cancer disease.Entities:
Mesh：
Year: 2019 PMID： 30776675 DOI： 10.1016/j.scr.2019.101405
Source DB: PubMed Journal: Stem Cell Res ISSN： 1873-5061 Impact factor: 2.020